Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

doi:10.1038/nature20554

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

Nature - 17 Nov 2016

De Henau Olivier, Rausch Matthew, Winkler David, Campesato Luis Felipe, Liu Cailian, Cymerman Daniel Hirschhorn, Budhu Sadna, Ghosh Arnab, Pink Melissa, Tchaicha Jeremy, Douglas Mark, Tibbitts Thomas, Sharma Sujata, Proctor Jennifer, Kosmider Nicole, White Kerry, Stern Howard, Soglia John, Adams Julian, Palombella Vito J, McGovern Karen, Kutok Jeffery L, Wolchok Jedd D, Merghoub Taha

Abstract excerpt

Recent clinical trials using immunotherapy have demonstrated its potential to control cancer by disinhibiting the immune system. Immune checkpoint blocking (ICB) antibodies against cytotoxic-T-lymphocyte-associated protein 4 or programmed cell death protein 1/programmed death-ligand 1 have displayed durable clinical responses in various cancers. Although these new immunotherapies have had a notable effect on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Tolerance

Share to Myeloid Cells

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to T-Lymphocytes, Cytotoxic

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 27828943
DOI: 10.1038/nature20554
PMCID: PMC5634331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.PMID 27828943Read ↗

Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell ImmunitySemantic proximity Read ↗

Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN LossSemantic proximity Read ↗

PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 SignalingSemantic proximity Read ↗

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapySemantic proximity Read ↗

PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesisSemantic proximity Read ↗

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint BlockadeSemantic proximity Read ↗

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read ↗

Tumor cell p38 inhibition to overcome immunotherapy resistanceSemantic proximity Read ↗

Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killingSemantic proximity Read ↗

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapySemantic proximity Read ↗

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySemantic proximity Read ↗

cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.